Headinvest, LLC Vertex Pharmaceuticals Inc Transaction History

Headinvest, LLC

$470 Million
Q4 2023

A detailed history of Headinvest, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Headinvest, LLC holds 1,048 shares of VRTX stock, worth $497,349. This represents 0.09% of its overall portfolio holdings.

Number of Shares

1,048

Previous 1,073 2.33%

Holding current value

$497,349

Previous $373,000 14.21%

% of portfolio

0.09%

Previous 0.08%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$343.0 - $410.68 $8,575 - $10,267	-25 Reduced 2.33%	1,048 $426,000
Q2 2023 Aug 23, 2023	SELL	$314.42 - $351.91 $7,231 - $8,093	-23 Reduced 2.1%	1,073 $377,000
Q1 2023 May 17, 2023	SELL	$283.23 - $323.1 $14,161 - $16,155	-50 Reduced 4.36%	1,096 $345,000
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $21,717 - $24,432	-76 Reduced 6.22%	1,146 $330,000
Q3 2022 Dec 28, 2022	BUY	$273.83 - $305.53 $2,738 - $3,055	10 Added 0.83%	1,222 $354,000

Q1 2022 May 13, 2022	SELL	$221.42 - $260.97 $3,764 - $4,436	-17 Reduced 1.38%	1,212 $316,000
Q4 2021 Feb 11, 2022	BUY	$177.01 - $223.45 $10,620 - $13,407	60 Added 5.13%	1,229 $270,000
Q3 2021 Nov 16, 2021	SELL	$181.39 - $202.99 $4,897 - $5,480	-27 Reduced 2.26%	1,169 $212,000
Q2 2021 Aug 30, 2021	BUY	$187.49 - $221.1 $7,687 - $9,065	41 Added 3.55%	1,196 $241,000
Q1 2021 May 13, 2021	BUY	$207.02 - $241.31 $239,108 - $278,713	1,155 New	1,155 $248,000
Q4 2020 Feb 16, 2021	SELL	$207.01 - $276.09 $213,841 - $285,200	-1,033 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$207.01 - $276.09 $213,841 - $285,200	1,033 New	1,033 $244,000

Others Institutions Holding VRTX

# of Institutions

1,625

Shares Held

222M

Call Options Held

1.35M

Put Options Held

1.49M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $122B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Headinvest, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headinvest, LLC with notifications on news.

Account